EA024893B9 - БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ - Google Patents

БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ

Info

Publication number
EA024893B9
EA024893B9 EA201370205A EA201370205A EA024893B9 EA 024893 B9 EA024893 B9 EA 024893B9 EA 201370205 A EA201370205 A EA 201370205A EA 201370205 A EA201370205 A EA 201370205A EA 024893 B9 EA024893 B9 EA 024893B9
Authority
EA
Eurasian Patent Office
Prior art keywords
benzo
calcium sensing
receptor modulators
sensing receptor
oxazin
Prior art date
Application number
EA201370205A
Other languages
English (en)
Other versions
EA201370205A1 (ru
EA024893B1 (ru
Inventor
Маноджкумар Рампрасад Шукла
Сарде Гангарам Анкуш
Пашпуте Дилип Випул
Маджид Башир Сайед
Махадео Бхаскар Трьямбаке
Четан Санджай Павар
Ганеш Навинчандра Готе
Санджеев Анант Кулкарни
Венката П. Палле
Раджендер Кумар Камбодж
Original Assignee
Люпин Атлантис Холдингс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Люпин Атлантис Холдингс Са filed Critical Люпин Атлантис Холдингс Са
Publication of EA201370205A1 publication Critical patent/EA201370205A1/ru
Publication of EA024893B1 publication Critical patent/EA024893B1/ru
Publication of EA024893B9 publication Critical patent/EA024893B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединения формулы (I) и способы их получения, которые применимы для лечения, контроля и/или облегчения заболеваний, расстройств, синдромов или состояний, ассоциированных с модуляцией чувствительных к кальцию рецепторов (CaSR). Способы лечения, контроля и/или облегчения заболеваний, расстройств, синдромов или состояний, ассоциированных с модуляцией чувствительных к кальцию рецепторов (CaSR), соединением формулы (I)
EA201370205A 2011-03-18 2012-03-16 БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ EA024893B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (3)

Publication Number Publication Date
EA201370205A1 EA201370205A1 (ru) 2014-01-30
EA024893B1 EA024893B1 (ru) 2016-10-31
EA024893B9 true EA024893B9 (ru) 2017-01-30

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370205A EA024893B9 (ru) 2011-03-18 2012-03-16 БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ

Country Status (15)

Country Link
US (1) US9464063B2 (ru)
EP (1) EP2686306B1 (ru)
JP (1) JP6033835B2 (ru)
KR (1) KR20140051846A (ru)
CN (1) CN103459377B (ru)
AP (1) AP2013007153A0 (ru)
AU (1) AU2012232706B2 (ru)
BR (1) BR112013023914A2 (ru)
CA (1) CA2829466A1 (ru)
EA (1) EA024893B9 (ru)
IL (1) IL228461A0 (ru)
MX (1) MX2013010670A (ru)
SG (1) SG193331A1 (ru)
WO (2) WO2012127385A1 (ru)
ZA (1) ZA201306837B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112679C2 (uk) * 2012-02-24 2016-10-10 Люпін Лімітед Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
IN2015MN00421A (ru) 2012-08-27 2015-09-04 Lupin Ltd
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
PE20160546A1 (es) 2013-10-25 2016-05-26 Novartis Ag Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3551176A4 (en) * 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3568135B1 (en) 2017-01-11 2021-04-07 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
CN114901273A (zh) * 2019-12-27 2022-08-12 鲁平有限公司 Casr调节剂的药物组合物及其方法和用途
EP4090654A1 (en) * 2020-01-17 2022-11-23 Lupin Limited Methods, processes and intermediates for preparing chroman compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090069A1 (fr) * 2000-05-24 2001-11-29 Centre National De La Recherche Scientifique (Cnrs) Composes possedant une activite calcimimetique
EP1882684A1 (en) * 2005-05-19 2008-01-30 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
US20100029687A1 (en) * 2006-11-16 2010-02-04 Astellas Pharma Inc. Piperidine derivative or salt thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
CN101233132A (zh) * 2005-05-09 2008-07-30 海德拉生物科学公司 调节trpv3功能的化合物
CN101547922B (zh) 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
AU2008328362A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 ＣａＳＲアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Ｅｇｒ装置及びこれを備えたエンジン装置
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090069A1 (fr) * 2000-05-24 2001-11-29 Centre National De La Recherche Scientifique (Cnrs) Composes possedant une activite calcimimetique
EP1882684A1 (en) * 2005-05-19 2008-01-30 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
US20100029687A1 (en) * 2006-11-16 2010-02-04 Astellas Pharma Inc. Piperidine derivative or salt thereof

Also Published As

Publication number Publication date
EP2686306B1 (en) 2017-01-04
ZA201306837B (en) 2015-05-27
CA2829466A1 (en) 2012-09-27
AU2012232706A1 (en) 2013-09-26
IL228461A0 (en) 2013-12-31
BR112013023914A2 (pt) 2016-12-13
JP2014510097A (ja) 2014-04-24
AP2013007153A0 (en) 2013-09-30
AU2012232706B2 (en) 2016-12-15
US20140018358A1 (en) 2014-01-16
WO2012127385A1 (en) 2012-09-27
US9464063B2 (en) 2016-10-11
NZ616676A (en) 2015-09-25
CN103459377B (zh) 2016-09-07
JP6033835B2 (ja) 2016-11-30
CN103459377A (zh) 2013-12-18
EP2686306A1 (en) 2014-01-22
EA201370205A1 (ru) 2014-01-30
EA024893B1 (ru) 2016-10-31
SG193331A1 (en) 2013-10-30
MX2013010670A (es) 2013-12-06
WO2012127388A1 (en) 2012-09-27
KR20140051846A (ko) 2014-05-02

Similar Documents

Publication Publication Date Title
EA024893B9 (ru) БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
TN2015000429A1 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
WO2011116356A3 (en) Positive allosteric modulators of group ii mglurs
EA201300887A1 (ru) Модуляторы s1p
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
UY32888A (es) Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparación y uso de las mismas
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
NZ700733A (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
PH12014501891A1 (en) Substituted chroman compounds as calcium sensing receptor modulators
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
IN2015MN00421A (ru)
WO2013005168A3 (en) Cannabinoid receptor modulators

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU